Treatment of Guillain-Barre syndrome with anti-T cell monoclonal antibodies.
Open Access
- 1 January 1991
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 54 (1) , 51-54
- https://doi.org/10.1136/jnnp.54.1.51
Abstract
Three patients with acute Guillain-Barré syndrome were treated early in the course of the disease with OKT3, an anti-T-cell monoclonal antibody. Each patient developed acute lymphopenia with specific depletion of T3-positive lymphocytes. Two patients had continued progression of clinical deficits for eight and 14 days. This suggests that T lymphocytes may not be essential for progression of Guillain-Barré syndrome at this stage of the disease.Keywords
This publication has 17 references indexed in Scilit:
- IN-VIVO ANTI-CD3 TREATMENT OF AUTOIMMUNE PATIENTSThe Lancet, 1989
- Systemic Reaction to the Anti–T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-αNew England Journal of Medicine, 1989
- Efficiency of plasma exchange in Guillain‐Barré syndrome: Role of replacement fluidsAnnals of Neurology, 1987
- Inflammatory demyelinating peripheral neuropathies associated with human T‐cell lymphotropic virus type III infectionAnnals of Neurology, 1987
- CEREBROSPINAL FLUID INFLAMMATION DURING OKT3 THERAPYThe Lancet, 1986
- Clinical correlation with anti‐peripheral‐nerve myelin antibodies in Guillain‐Barré syndromeAnnals of Neurology, 1986
- Autonomic Disturbances in the Guillain-Barre SyndroméSeminars in Neurology, 1984
- Human in vivo antigenic modulation induced by the anti‐T cell OKT3 monoclonal antibodyEuropean Journal of Immunology, 1982
- Guillain‐Barré syndrome and Hodgkin's disease: Three cases with immunological studiesAnnals of Neurology, 1977
- THE INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITISMedicine, 1969